Concord Drugs Limited reported earnings results for the second quarter and six months ended September 30, 2021. For the second quarter, the company reported sales was INR 98.31 million compared to INR 165.67 million a year ago. Revenue was INR 98.59 million compared to INR 166.12 million a year ago. Net income was INR 4.58 million compared to INR 0.8066 million a year ago. Basic earnings per share from continuing operations was INR 0.52 compared to INR 0.092 a year ago. Diluted earnings per share from continuing operations was INR 0.52 compared to INR 0.092 a year ago. For the six months, sales was INR 300.5 million compared to INR 347.7 million a year ago. Revenue was INR 301 million compared to INR 348.36 million a year ago. Net income was INR 11.46 million compared to INR 2.46 million a year ago. Basic earnings per share from continuing operations was INR 1.31 compared to INR 0.281 a year ago. Diluted earnings per share from continuing operations was INR 1.31 compared to INR 0.281 a year ago.